Associations between multiple metabolic biomarkers with steatotic liver disease subcategories: A 5-year Chinese cohort study

作者：Hongli Chen, Siyu Chen, Dan Liu, Yebei Liang, Huating Li, Yuqian Bao, Zhi‐Jun Zhu, Keqing Dong, Wen Li, Feng Liang, Di Cheng, Fusong Jiang, Wei Li, Xuhong Hou, Weiping Jia · 发表于：Cell Reports Medicine · 年份：2025 · DOI：10.1016/j.xcrm.2024.101884 · 被引用次数：13 · 研究领域：Fibroblast Growth Factor Research、Liver Disease Diagnosis and Treatment、Kruppel-like factors research

The effectiveness of established biomarkers for non-alcoholic fatty liver disease (NAFLD) within the updated framework of steatotic liver disease (SLD) remains uncertain. This cohort study examines the association of four metabolic biomarkers-retinol-binding protein 4 (RBP-4), fibroblast growth factor 21 (FGF-21), adiponectin, and osteocalcin-with SLD and its subtypes: metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction with alcohol-related liver disease (MetALD)/alcohol-related liver disease (ALD). Among 3,504 Chinese participants aged 55-70, 938 (26.8%) have developed SLD over 5 years, including 871 with MASLD and 67 with MetALD/ALD. The findings indicate that models incorporating RBP-4, FGF-21, adiponectin, and osteocalcin improve predictive accuracy for SLD beyond conventional models. Notably, adiponectin emerges as the most versatile marker, while elevated baseline levels of FGF-21 or RBP-4 indicate specific needs for metabolic or alcohol-related interventions, respectively, supporting tailored precision medicine strategies.